The expansion addresses a central limitation of cancer genomics. Sequencing and other molecular methods can catalogue alterations in tumors, yet the clinically important question is often which of those alterations cancer cells actually require to survive. Project Achilles at the Broad Institute and Project DRIVE at Novartis addressed this through large-scale RNA interference screens, while the Cancer Cell Line Encyclopedia linked dependencies in hundreds of cell lines to genomic features. Computational filtering reduced off-target effects, and CRISPR subsequently offered more specific gene inactivation. Together, these resources created DepMap, which connects molecular features with essential genes across thousands of conventional cell lines.

Conventional models nevertheless represent only part of human cancer. Some tumors, including many prostate cancers, adapt poorly to two-dimensional culture. Established cell lines may also lack the treatment history of the patients from whom they originated and retain little of the cellular diversity present within a tumor. The three new studies therefore assembled complementary collections of patient-derived organoids and other next-generation models. In addition to enlarging the number of systems available for perturbation, they asked whether the new models retain tumor identity, can support rigorous genome-wide screens, and expose dependencies missed by conventional cell lines.

The first assessment compared models with their parental tumors and produced encouraging but incomplete results. Across assay-specific subsets, 92% to 98% of Human Cancer Models Initiative models met genomic or transcriptional measures of concordance. Sanger researchers reported strong genomic concordance across 171 organoid–tumor pairs. Broad’s Celligner analysis found that 69% of next-generation models matched their expected lineage, compared with 35% of conventional cell lines. Fewer than 2% of the newer models occupied an undifferentiated transcriptional cluster, whereas more than 25% of conventional cell lines did. These findings indicate that patient-derived models can preserve cancer-associated molecular features substantially better than many long-established lines.

That fidelity has clear practical limits. Patient-derived models are difficult to establish, and their genomes and cellular identities can change in culture. Sanger generated 256 organoids from 907 submitted samples, with low tumor cellularity and cultures that could not be renewed accounting for many failures. HCMI models retained 81% of tumor driver events, but 10% developed whole-genome doubling that was absent from the parental tumor. Sanger also observed whole-genome doubling and chromothripsis more frequently in organoids. In a more specific pattern, extrachromosomal EGFR copy number was higher in the parental tumor in 80% of glioblastoma pairs examined by HCMI.

Cellular state proved even less stable than the presence of a cancer-driving mutation. At single-cell resolution, only three of seven profiled glioblastoma models retained the malignant cell states seen in their parental tumors, while three shifted toward a predominantly mesenchymal state. Broad found that breast cancer organoids sometimes lacked enough ESR1 and ERBB2 expression to reproduce the corresponding dependencies, and none of 12 prostate cancer models retained a recognizable prostate lineage identity by Celligner. The results show why retaining a driver mutation is not enough: a model can preserve a genomic lesion while losing the state that makes a tumor dependent on it, or it can acquire a dependency without faithfully retaining the original cellular program.

Despite these complications, the new models proved suitable for genome-scale experiments. Broad’s organoid screens separated essential from non-essential genes as effectively as conventional screens, while Sanger obtained quality-controlled data from 85% of models in which screens were attempted. These results establish that patient-derived systems can support large perturbations across multiple genes. They do not remove every interpretive problem, however. Dependencies in steroid and isoprenoid biosynthesis may be influenced by culture conditions rather than the original tumor environment. Bulk measurements can also conceal dependencies restricted to particular cellular subpopulations, an issue especially relevant in tumors that contain several distinct states.

The clearest value of the expanded maps lies in their ability to resolve dependencies that broad genomic labels cannot explain. In esophageal and gastric organoids, KRAS amplification predicted dependency on stearoyl-CoA desaturase most strongly, and the finding was validated with two inhibitors. Colorectal organoids carrying KRAS G12 variants remained dependent on EGFR and PTPN11, whereas a KRAS Q61H model resisted EGFR inhibition. Microsatellite instability was likewise insufficient to predict WRN dependency: four organoids lacked that dependency and did not carry the expanded TA repeats associated with it. These are model observations, not clinical efficacy findings, but they demonstrate that the same cancer label can conceal different underlying requirements.

Cellular composition added another dimension to the maps. Low ENO2 expression predicted ENO1 dependency more strongly in patient-derived models than in conventional cell lines. Glial glioblastoma models showed CDK6 dependency associated with CDKN2A loss, while organoids expressing a PDAC-classical and MUC-high program depended more heavily on WNT pathway components. Single-cell profiling of 22 advanced prostate cancer organoids identified seven lineage states that frequently coexisted within individual models, helping explain why bulk gene-depletion measurements can vary. This analysis also implicated the aryl hydrocarbon receptor in plasticity. Dependencies could shift with treatment as well: an esophageal organoid obtained at relapse had lost MYC amplification, showed reduced KRAS and DNMT1 dependencies, gained PSMB5 dependency and exhibited corresponding changes in drug sensitivity.

The central implication is that dependency is not determined by a tumor’s broad genomic category alone. It reflects the particular alteration present, the cellular state expressing that alteration and the treatment history embedded in the model. Patient-derived organoids help expose those combinations, offering a more detailed map of survival requirements than conventional cell lines. The evidence remains preclinical, and the studies do not establish that the new dependencies will produce better drugs or improve patient outcomes. Conventional DepMap screens have nevertheless already motivated clinical development programs for targets such as PRMT5 in MTAP-deleted tumors and WRN in microsatellite-unstable cancers. Whether the added biological resolution of the expanded map can be converted into useful therapies will depend on further validation, and on building models that faithfully preserve the lineage states of common hormonally driven cancers such as breast and prostate cancer.

Subject of Research: Cancer dependency mapping in patient-derived organoid models and organoid-specific genetic vulnerabilities

Article Title: Expanding DepMap: is the juice worth the squeeze?

Article References: Zaidi, S., & Sawyers, C. L. (2026). Expanding DepMap: is the juice worth the squeeze?. Cell Research. https://doi.org/10.1038/s41422-026-01311-y

Image Credits: AI Generated

DOI: 10.1038/s41422-026-01311-y

Keywords: DepMap, cancer dependency maps, patient-derived models, organoids, cancer genomics, genetic vulnerabilities, KRAS, SCD, cellular plasticity, drug discovery, Expanding, juice

The starting point of the review is the physical assault that radiotherapy delivers. Ionizing radiation deposits energy that breaks DNA directly and, indirectly, floods cells with reactive oxygen species that damage proteins, lipids, and genomes alike. The dose, the fractionation schedule, and the type of radiation used all determine the character of this pressure. Cells that survive the initial insult do so by activating their DNA damage response machinery, a coordinated network of sensors, transducers, and effectors that pauses the cell cycle, repairs double-strand breaks through pathways such as non-homologous end joining and homologous recombination, and, when damage is overwhelming, triggers senescence or apoptosis. But the review emphasizes that DNA repair is only the first layer of a much deeper program of tolerance.

That deeper program is cellular plasticity. Rather than dying or fully recovering, a subset of surviving cells appears to enter altered, quasi-stable states that echo phenomena described in drug-treated tumors. The authors catalog several of these: persister-like states in which cells reversibly suspend proliferation; cancer stem cell-like states marked by molecules such as CD44 and aldehyde dehydrogenase, with enhanced self-renewal and repair capacity; senescence-like states, detectable in part by senescence-associated beta-galactosidase, in which cells remain metabolically alive but stop dividing and can secrete inflammatory signals; and hybrid epithelial-mesenchymal transition states that combine adhesive and migratory traits. Crucially, these states are not permanent identities. They are plastic, meaning the same residual cell may drift between them, and that fluidity makes them extraordinarily difficult to eliminate with any single targeted agent.

Alongside chromatin remodeling and transcriptional stress memory, which allow cells to carry a kind of biochemical recollection of the radiation they endured, these plastic states form the tumor-cell-intrinsic half of the radioresistance story. The review is careful to note that this intrinsic component complements rather than replaces classical radiosensitivity, which depends on factors such as oxygenation, cell-cycle phase, and repair capacity. What is new is the recognition that intrinsic tolerance alone cannot explain why recurrences so often emerge in predictable locations and time windows. For that, the authors argue, one must look outward, to the microenvironment that surrounds and stabilizes the surviving cells.

The concept of the tolerant niche is the conceptual heart of the paper. The authors describe several recurring microenvironmental configurations that act as sanctuaries for residual disease. Hypoxic niches are perhaps the best known: low oxygen reduces the radiation-induced free radical chemistry that makes oxygen so potent a radiosensitizer, and hypoxia simultaneously drives stem-like and invasive transcriptional programs. Perivascular niches, the zones around surviving blood vessels, shelter quiescent tumor cells and are rich in protective signaling. Niches dominated by cancer-associated fibroblasts and remodeled extracellular matrix provide both mechanical and biochemical support, secreting growth factors and stiffening tissue architecture in ways that dampen radiation lethality. Metabolic niches, shaped by nutrient scarcity and altered metabolite exchange, and myeloid niches, populated by tumor-associated macrophages, myeloid-derived suppressor cells, and regulatory T cells that suppress antitumor immunity, complete the picture. In each case, the niche does not merely coexist with tolerant cells; it actively maintains their state.

One of the review’s most useful contributions is its insistence that these mechanisms vary substantially among tumor types. The relative weight of hypoxia, stromal shielding, immune suppression, or stem-like plasticity differs between, for example, glioblastoma, pancreatic ductal adenocarcinoma, and lung cancer, and the authors caution against assuming that a strategy validated in one context will transfer to another. This heterogeneity has practical consequences for how the field measures residual disease. The authors assess the tools available and find them strikingly unequal in maturity. Functional imaging, including hypoxia-targeted PET tracers and advanced MRI sequences, and liquid biopsy based on circulating tumor DNA, offer selected clinical readouts that can already be deployed in trials to track residual disease and recurrence risk over time.

Spatial omics technologies, by contrast, which map gene expression and other molecular features across intact tissue sections, currently serve mainly as discovery and validation tools rather than clinical diagnostics. They are indispensable for identifying which cells occupy which niches and how those relationships change after irradiation, but sampling limitations, cost, and analytical complexity keep them out of routine practice. The review is candid about this gap: the field can describe tolerant niches in exquisite detail in resected specimens, yet it largely lacks the longitudinal, minimally invasive measurements needed to watch them form and dissolve in living patients. Bridging that gap, the authors suggest, will require combining serial ctDNA monitoring with imaging and, where feasible, repeat tissue sampling.

On the therapeutic side, the review outlines both evidence-based and investigational strategies for what the authors term niche-informed radiotherapy. Established approaches include hypoxia modification, dose escalation and altered fractionation, and combinations with DNA damage response inhibitors that disable the repair programs tolerant cells rely on. More speculative candidates target the niche itself: agents that reprogram cancer-associated fibroblasts, normalize tumor vasculature, modulate myeloid suppressor cells, or relieve immune suppression so that checkpoint blockade can act on residual disease. Senolytic strategies aimed at clearing senescence-like cells, and agents designed to push plastic persister states out of their protective equilibrium, also feature among the investigational options. The unifying principle is that candidate combinations should be validated against the specific niche dependencies of a given tumor before clinical adaptation, rather than applied indiscriminately.

The authors are equally clear about the obstacles standing between this framework and the clinic. Conceptually, tolerant niches are dynamic and heterogeneous, so static snapshots may mislead. Sampling remains a fundamental problem, since the most informative regions of a treated tumor are often inaccessible. Implementation faces the usual barriers of combination-therapy trials, toxicity management, and the absence of validated biomarkers that identify which patients carry which niche dependencies. None of these limitations, in the authors’ view, undermines the framework; they simply define the work that remains. The review, which was supported by numerous Chinese national and institutional research programs and published open access on 9 October 2026, is intended as a roadmap rather than a final verdict.

If the tolerant niche concept holds up under experimental and clinical scrutiny, its implications for oncology could be considerable. Recurrence after radiotherapy would no longer be viewed as a mysterious resurgence but as the predictable product of a documented sequence: radiation pressure, followed by the emergence of plastic residual states, followed by their stabilization within hypoxic, stromal, metabolic, and immune sanctuaries. Each step in that sequence offers an interception point, a moment when a rationally chosen combination therapy might extinguish the embers before they reignite. Turning that vision into practice will demand the longitudinal monitoring tools and niche-specific combination trials the review calls for, but it reframes one of radiotherapy’s oldest frustrations as a solvable, spatially defined problem in tumor ecology.

Subject of Research: Radioresistance and tumor recurrence through cellular plasticity and radiation-induced tolerant niches in the tumor microenvironment

Article Title: Radioresistance and tumor recurrence: cellular plasticity, tolerant niches, and therapeutic opportunities

Article References: Zhang, Y., Li, H., Lv, S., Peng, L., Meng, W., Guo, J., Lu, Y., Chen, W., Yang, W., & Peng, X. (2026). Radioresistance and tumor recurrence: cellular plasticity, tolerant niches, and therapeutic opportunities. Molecular Cancer. https://doi.org/10.1186/s12943-026-02806-3

Image Credits: AI Generated

DOI: 10.1186/s12943-026-02806-3

Keywords: radioresistance, radiotherapy, tumor recurrence, tolerant niches, cellular plasticity, DNA damage response, tumor microenvironment, cancer stem cells, hypoxia, residual disease, spatial omics, ctDNA

The research, led by Sarah Frieda Becker, Marie-Charlotte Morin, Julien Lambert, Shashi Kumar Suman, Francesco Nicola Carelli, Alex Appert, Stéphane Roth, Sarah Hoff-Yoessle, Jessica D. Medina-Sanchez, Manuela Portoso, Julie Ahringer, and Sophie Jarriault, focuses on one of the most remarkable examples of natural cellular plasticity in biology: the conversion of a rectal cell known as the Y cell into a neuron called the PDA. This Y-to-PDA transdifferentiation happens spontaneously during normal worm development, without any injury, experimental reprogramming, or artificial manipulation. Because it occurs reliably and naturally, it offers scientists a clean window into how multicellular organisms permit, control, and restrain changes in cell identity.

For more than a decade, cellular plasticity has been one of the hottest topics in biology. The ability of one cell type to become another underlies both the promise of regenerative medicine and the danger of cancer, where differentiated cells lose their specialized functions and revert to uncontrolled proliferation. Yet while researchers have catalogued many factors that actively push cells toward new identities, the mechanisms that actively prevent such changes, and the ways organisms get around those barriers when change is needed, remain far less well understood. The new study addresses precisely this gap, arguing that the molecular machinery of natural transdifferentiation is more diverse and more layered than previously appreciated.

Using careful genetic analysis in C. elegans, the team showed that lin-15A operates in parallel to plasticity factors that had already been described in the Y-to-PDA conversion. This parallel action is significant. It means that lin-15A is not simply another cog in a known machine but represents a distinct branch of the regulatory network, one that had gone unnoticed because it does not fit the conventional profile of a reprogramming factor. When the researchers examined worms carrying null mutations that eliminate lin-15A function entirely, they found that the transdifferentiation process was compromised, revealing that the gene is required for the natural conversion to unfold properly.

The most striking finding, however, concerns what lin-15A actually does. Rather than acting as an engine that pushes the Y cell toward its neuronal fate, the evidence suggests that LIN-15A works by antagonizing several chromatin-modifying complexes. Chromatin, the packaged form of DNA inside the cell nucleus, is the physical substrate of cell identity. Specialized complexes chemically modify chromatin to lock in the expression patterns that define a differentiated cell, effectively safeguarding that identity against change. These identity safeguarding mechanisms are powerful, and they explain why most cells, even under stress, rarely switch types spontaneously. By interfering with multiple such complexes simultaneously, LIN-15A appears to loosen these locks, lowering the barrier that would otherwise prevent the Y cell from beginning its transformation.

This distinction between driving and licensing is the conceptual heart of the study. The authors propose a two-part model for how controlled cell identity conversions are coordinated in living organisms. In this model, plasticity factors function as Drivers, molecules that actively steer a cell toward its new identity by activating the gene programs of the target cell type. Licensers, by contrast, such as lin-15A, attenuate identity safeguarding mechanisms, clearing the path so that the Drivers can do their work. Neither class alone is sufficient; the conversion requires both the removal of barriers and the provision of directional force. This framework offers a new vocabulary for thinking about natural reprogramming and suggests that similar licensing activities may exist in other transdifferentiation systems across the animal kingdom.

Perhaps the most surprising result is that even cells that are developmentally programmed to undergo transdifferentiation still exhibit reprogramming barriers. One might assume that a cell destined by evolution to change identity would face no resistance at all, that the program would simply run like any other developmental script. The data show otherwise. The Y cell, despite being hardwired for conversion, still needs help overcoming the chromatin-based defenses of its rectal identity. This finding underscores how deeply entrenched cell identity is, and how even nature’s own reprogramming events must actively dismantle protective mechanisms rather than simply switch on new ones.

Equally intriguing is the context-dependence of lin-15A’s role. The study demonstrates that lin-15A is not a core plasticity factor in its own right. It does not universally promote cellular transformations wherever it is expressed. Instead, it functions as a plasticity factor specifically in the Y cell context. This context specificity raises fascinating questions about how licensing activities are targeted to particular cells and particular moments in development. It suggests that the interplay between a gene’s intrinsic biochemical activity and the cellular environment in which it acts determines whether it serves as a general regulator or a highly specialized enabler of change.

The implications extend well beyond worm biology. If natural transdifferentiation relies on a division of labor between Drivers and Licensers, then engineered reprogramming in medicine may need to account for both components. Current approaches to generating replacement cells for regenerative therapies typically focus on delivering powerful driving factors, such as transcription factor cocktails, to force cells into new identities. The new work suggests that a complementary strategy, deliberately weakening the chromatin-based safeguards of the starting cell, could make such conversions more efficient and more faithful to natural processes. Conversely, in cancer, where cells inappropriately shed their differentiated identities, understanding licensing mechanisms could reveal new therapeutic targets: ways to reinforce identity safeguarding and prevent malignant dedifferentiation.

The study also highlights the enduring value of C. elegans as a model for fundamental discovery. Because the worm’s cells can be followed individually through development, and because the Y-to-PDA conversion is a natural event that can be observed and genetically dissected with precision, researchers can identify mechanisms that would be nearly impossible to isolate in more complex systems. The identification of a THAP domain gene as a licensing factor adds a new family of proteins to the plasticity toolbox and opens avenues for exploring whether related genes perform analogous roles in other organisms, including humans. As the authors conclude, diverse molecular activities coordinate controlled cell identity conversions, and recognizing that some of these activities work by removing barriers rather than providing direction may fundamentally change how scientists approach the problem of cellular identity, both in the laboratory and, eventually, at the bedside.

Subject of Research: The role of the lin-15A gene in licensing natural Y-to-PDA transdifferentiation in C. elegans by antagonizing chromatin-based identity safeguarding mechanisms

Article Title: The SynMuvA lin-15A licenses natural transdifferentiation by antagonizing identity safeguarding mechanisms

Article References: Becker, S. F., Morin, M.-C., Lambert, J., Suman, S. K., Carelli, F. N., Appert, A., Roth, S., Hoff-Yoessle, S., Medina-Sanchez, J. D., Portoso, M., Ahringer, J., & Jarriault, S. (2026). The SynMuvA lin-15A licenses natural transdifferentiation by antagonizing identity safeguarding mechanisms. PLOS Genetics, 22(9), e1012290. https://doi.org/10.1371/journal.pgen.1012290

Image Credits: AI Generated

DOI: 10.1371/journal.pgen.1012290

Keywords: cell plasticity, transdifferentiation, lin-15A, Caenorhabditis elegans, chromatin, cell identity, PLOS Genetics, reprogramming, THAP domain, developmental biology, gene regulation, regenerative medicine

Pancreatic alpha cells are best known as the body’s counterweight to insulin. While beta cells release insulin to lower blood glucose, alpha cells secrete glucagon, a hormone that raises blood sugar by mobilizing glucose stores from the liver. The tight coordination of these two hormones is fundamental to metabolic health, and its breakdown lies at the heart of both major forms of diabetes. Yet alpha cells have long lived in the shadow of their insulin-secreting neighbors. Only in recent years has the field come to appreciate that alpha cells possess their own finely tuned developmental program, a distinct epigenetic and transcriptional landscape, and a surprising capacity for plasticity, the ability to switch fate under certain pressures and transform into cells that resemble beta cells.

That plasticity is a double-edged sword. On one hand, it represents a tantalizing therapeutic opportunity: if the body’s own alpha cells can be coaxed into becoming functional beta cells, they could replace the insulin-producing cells destroyed or dysfunctional in diabetes. Previous work has shown that forced expression of transcription factors such as PDX1 and MAFA, delivered by viral gene therapy, can reprogram alpha cells into insulin-producing cells and even reverse autoimmune diabetes in mouse models. On the other hand, unplanned and incomplete fate conversion is potentially harmful. Cells caught between identities may perform neither function well, secreting inappropriate hormone combinations and destabilizing glucose control. Understanding the molecular brakes that normally prevent such drift is therefore as important as understanding the accelerators that drive it.

The new study identifies one of those brakes as a component of the cell’s RNA-processing equipment. N6-methyladenosine, commonly abbreviated m6A, is installed on mRNA by a multi-protein writer complex whose catalytic core includes the methyltransferase METTL14 together with its partner METTL3. The modification influences nearly every stage of an mRNA molecule’s life, including how it is spliced, exported from the nucleus, translated into protein, and eventually degraded. Because m6A affects the fates of thousands of transcripts simultaneously, it acts as a broad regulator of gene expression, shaping cell state without altering the underlying DNA sequence. Previous work had already shown that m6A methylation is required for human beta-cell identity and function, and that METTL14-dependent methylation governs early pancreatic endocrine differentiation, but the role of the modification in mature alpha cells remained unexplored.

To probe that question, the researchers deleted METTL14 specifically in alpha cells, stripping the cells of their capacity to deposit m6A marks on newly made mRNA. The consequences were immediate and instructive. Amino acid-stimulated glucagon secretion, the signature function of alpha cells, was impaired. Loss of the methylation machinery also destabilized the alpha-cell state itself: the expression of genes that define and sustain alpha-cell identity became disorganized, and the cells began to show features characteristic of immature, insulin-secreting, beta-cell-like fates. In other words, without its mRNA methylation marks, the alpha cell no longer reliably remembered what it was supposed to be.

The mechanistic logic is elegant. Alpha-cell identity is maintained by a network of transcription factors and regulatory RNAs whose balanced expression keeps the glucagon program active while repressing alternative fates. m6A methylation contributes to that balance by controlling the stability and translation of key transcripts. When METTL14 is lost, the methylation patterns that help enforce the alpha-cell program disappear, the network loses its grip, and plasticity pathways that are normally silenced can come to the fore. The result is a gradual shift in cell state, mirroring the fate conversions observed when developmental regulators are experimentally forced into action, but arising here from the absence of a housekeeping modification rather than the addition of a reprogramming factor.

These results extend a growing body of evidence that the epitranscriptome is not a passive decoration of RNA but an active pillar of cellular identity in the endocrine pancreas. The 2019 finding that m6A regulates human beta-cell biology in physiological states and in type 2 diabetes established the modification’s importance on the insulin-producing side of the islet. The new work completes the picture on the glucagon-producing side, showing that alpha cells depend on the same machinery to preserve their own specialized function. Together, the studies suggest that m6A methylation acts as a general safeguard of endocrine cell fate, protecting both major hormone-producing lineages of the pancreatic islet from identity erosion.

The implications for diabetes research are considerable. If loss of mRNA methylation promotes alpha-to-beta-like plasticity, then the modification could represent a checkpoint that regenerative therapies must either respect or deliberately manipulate. Strategies aimed at converting alpha cells into replacement beta cells might need to account for the destabilizing or stabilizing effects of the m6A machinery, and conversely, drugs that modulate m6A writers, erasers, or reader proteins could in principle be used to either encourage or restrain fate switching. More broadly, the work raises the possibility that some forms of islet dysfunction in diabetes may reflect age-related or stress-related decline in RNA modification pathways, a hypothesis that is now testable with the expanding toolkit of epitranscriptomic mapping methods.

The study also adds nuance to the concept of cellular plasticity itself. Rather than being triggered solely by external injury or forced transcription factor expression, fate drift can emerge from the quiet failure of an RNA-level maintenance system. This reframes alpha-cell identity as a state that must be actively and continuously renewed through post-transcriptional regulation, not merely switched on during development and left to run. The research team’s demonstration that METTL14 deletion simultaneously impairs amino acid-regulated glucagon secretion and promotes beta-like conversion links two previously separate observations, defective alpha-cell function and aberrant plasticity, into a single mechanistic framework.

For now, the immediate significance of the work is conceptual: it identifies mRNA methylation as a guardian of alpha-cell identity and provides a molecular explanation for how endocrine cells resist, or fail to resist, the pull of alternative fates. The long-term significance may prove larger. As the field continues to map the epitranscriptomic codes that stabilize or destabilize cell states, the prospect of precisely controlling cellular identity, whether to protect failing islets or to regenerate them, moves from speculation toward concrete pharmacology. The alpha cell, long considered a secondary player in diabetes biology, has now claimed a central role in that emerging story.

Subject of Research: The role of m6A mRNA methylation by METTL14 in maintaining pancreatic alpha-cell identity and preventing cellular plasticity toward beta-cell-like fates.

Article Title: mRNA methylation safeguards pancreatic α-cell identity against cellular plasticity

Article References: mRNA methylation safeguards pancreatic α-cell identity against cellular plasticity. (2026). Nature Metabolism, 8(9), 1841–1842. https://doi.org/10.1038/s42255-026-01594-w (Author names are not included in the publisher’s citation export.)

Image Credits: AI Generated

DOI: 10.1038/s42255-026-01594-w

Keywords: m6A methylation, METTL14, pancreatic alpha cells, epitranscriptomics, glucagon, cellular plasticity, beta cells, diabetes, gene regulation, RNA modification, islet biology, cell identity

The consortium’s central message is that the intestinal stem cell is not a fixed identity but a flexible state dictated by its surroundings. Historically, researchers divided intestinal stem cells into two camps: actively self-renewing cells marked by the gene Lgr5, which continuously fuel the everyday turnover of the epithelium, and a facultative or ‘reserve’ population, sometimes called revival stem cells, that normally rests but springs into action after catastrophic injury. Landmark studies identified Bmi1, Hopx, and other markers for these reserve cells, and work by Tian and colleagues showed that a reserve population could render Lgr5-positive cells dispensable under certain conditions. The new Roadmap argues that neither population is intrinsically determined; rather, homeostatic and regenerative properties emerge from signals emanating from a specialized local niche, the microenvironment that cradles the stem cells and instructs their behavior.

That niche has turned out to be far more complex than early models suggested. In the small intestine, Paneth cells interdigitated among the stem cells at the crypt base supply Wnt ligands, antimicrobial peptides, and metabolic support, although studies by Kim, Escudero, and Shivdasani demonstrated that Lgr5 stem cells can function even without Paneth cells, pointing to redundant support systems. Surrounding the crypts lies a constellation of mesenchymal cell types, each with distinct jobs. PDGFRα-positive pericryptal stromal cells and GLI1-expressing cells serve as critical sources of Wnts and the Wnt-amplifying protein RSPO3, while FOXL1-positive telocytes, CD34-positive mesenchymal cells, and distinct smooth muscle layers contribute additional Wnt ligands, bone morphogenetic protein gradients, and structural organization. Graded BMP signaling within the crypt architecture, as shown by Kraiczy and colleagues, even directs the self-organization of the Wnt-secreting niche itself, revealing an intricate feedback loop between epithelium and stroma.

Beyond fibroblasts, the consortium highlights an expanding cast of niche regulators. Lymphatic vessels act as signaling hubs, with lymphangiocrine signals required for proper repair after cytotoxic injury. Enteric glial cells, macrophages, and type 3 innate lymphoid cells all modulate stem cell activity, the latter through the cytokine interleukin-22, which promotes stem-cell-mediated epithelial regeneration and protects stem cells from immune-mediated damage. Even nerves participate: adrenergic nerves regulate intestinal regeneration through IL-22 signaling from innate lymphoid cells, and nociceptive neurons have been implicated in tumor progression via a CGRP-RAMP1 axis. Mechanosensing adds another dimension, with PIEZO-dependent mechanical signals proving essential for stem cell fate decisions. The picture that emerges is of a layered, multi-tissue ecosystem in which epithelial, mesenchymal, immune, vascular, lymphatic, and neural components jointly govern when stem cells divide, differentiate, or revert to a fetal-like regenerative program.

Cellular plasticity sits at the heart of this regenerative capacity. When Lgr5-positive stem cells are ablated, a remarkable variety of differentiated and progenitor cells can dedifferentiate and rebuild the stem cell compartment. Dll1-positive secretory progenitors, enterocyte-lineage daughters, Paneth cells responding to Notch activation, enteroendocrine lineage cells, and even tuft cells, which Huang and colleagues showed act as regenerative stem cells in the human intestine, have all been documented to revert. Single-cell transcriptomics revealed a revival stem cell state marked by fetal programs, and parasitic helminths were found to induce fetal-like reversion in the niche as part of the immune response. Chromatin studies explain how this is possible: the intestinal epithelium maintains broadly permissive chromatin that allows rapid switching between lineages, while factors such as Ascl2, ATOH1 phosphorylation, and Frizzled5-controlled chromatin accessibility orchestrate the dedifferentiation process. In disease, this plasticity is a double-edged sword, since the same reserve and revival programs that heal wounds can seed radioresistant, cancer-initiating populations.

Translating this biology into therapies has been propelled by organoid technology, one of the field’s transformative breakthroughs. In 2009, Sato and colleagues showed that single Lgr5 stem cells could build crypt-villus structures in vitro without a mesenchymal niche, and Ootani’s team sustained intestinal epithelium in a Wnt-dependent stem cell culture system the same year. Human colon, adenoma, and Barrett’s epithelium organoids followed in 2011, as did the directed differentiation of human pluripotent stem cells into intestinal tissue by Spence and colleagues. The technology has since matured dramatically: scaffold-guided morphogenesis produces homeostatic mini-intestines, organoid-derived tissues have repaired damaged bowel in vivo, patient-derived jejunal mucosal grafts have been engineered from children with intestinal failure, and organ-repurposing approaches have treated short bowel syndrome in preclinical models. Human intestinal organoids transplanted into humanized mice develop immune tissue, and coordinated differentiation protocols now generate organoids with functional enteric neurons and vasculature, bringing engineered gut tissue closer to clinical reality.

The consortium also emphasizes how organoids and microfluidic gut-on-a-chip systems have become indispensable for studying host-pathogen interactions. Complex human gut microbiomes have been cultured in anaerobic intestine-on-a-chip devices, and human colon models have revealed uncoupled apical and basal cytotoxicity during early Clostridioides difficile toxin exposure. These platforms allow researchers to interrogate how pathogens reshape the stem cell compartment and how microbial metabolites, such as microbiota-derived lactate, accelerate stem-cell-mediated epithelial development. Innate immune receptors on the stem cells themselves, including Toll-like receptor 4 and NOD2, which protects LGR5-positive cells from reactive oxygen species through mitophagy, directly link microbial sensing to regenerative capacity, suggesting that microbiome manipulation could become a therapeutic lever for mucosal healing.

Pharmacological strategies form the second pillar of the therapeutic roadmap. R-spondin ligands, potent amplifiers of Wnt signaling, have been shown to induce intestinal stem cells, augment chemoradioprotection, promote colonic regeneration, and ameliorate experimental colitis, while surrogate Wnt agonists that phenocopy canonical signaling support organoid growth and show promise for FZD-specific activation of repair pathways. Glucagon-like peptide-2 agonists, already approved for short bowel syndrome, stimulate S-phase entry of Lgr5-positive stem cells and support stem cell and Paneth cell repair during graft-versus-host disease, with newer agents such as glepaglutide showing anti-inflammatory and mucosal regenerative effects. Structure-based design has even decoupled the tissue-protective functions of interleukin-22 from its pro-inflammatory actions, opening the door to safer regenerative cytokine therapies. The consortium cautions, however, that stimulating proliferation carries oncogenic risk, and that niche dysregulation is predicted to underlie compromised regeneration in conditions such as inflammatory bowel disease, where stem cells retain epigenetic memories of inflammation.

The Roadmap closes with a candid inventory of remaining knowledge gaps. Human intestinal stem cells differ from their mouse counterparts in ways that matter for therapy, and spatial atlases of the adult human intestine, single-cell maps of human development, and spatial transcriptomic surveys of regeneration are only now filling the void. Bioengineered colon organoids with in vivo-like complexity, bioprinted tissues recapitulating macro-scale self-organization, and instant collagen assembly for tissue engineering are pushing manufacturing capabilities forward, while lessons from the first pluripotent stem cell therapies entering the clinic, including stem-cell-derived islets for diabetes and retinal cells for macular degeneration, offer a template for regulatory and safety pathways. What the ISCC’s fifteen-year arc demonstrates is that the intestine, once considered too dynamic and complex to rebuild, has yielded its construction secrets to systematic, collaborative biology. The remaining challenge is engineering: assembling niche cells, immune compartments, vasculature, and nerves into transplantable tissue that can survive, integrate, and function in patients whose own guts can no longer keep pace. If the consortium’s roadmap holds, the era of stem-cell-built intestines may be closer than anyone dared predict when the effort began.

Subject of Research: Intestinal stem cell biology and stem cell-based strategies for intestinal regeneration and tissue engineering

Article Title: Building and regenerating intestines by manipulating intestinal stem cells

Article References: Kuo, C. J., Blutt, S., Donowitz, M., Estes, M. K., Guha, C., Klein, O. D., Li, L., Niland, J. C., Santos, A. J. M., Shivdasani, R. A., Spence, J. R., Swanson, C. J., Wang, T. C., Yan, K. S., Zachos, N. C., & Helmrath, M. A. (2026). Building and regenerating intestines by manipulating intestinal stem cells. Nature Reviews Gastroenterology & Hepatology. https://doi.org/10.1038/s41575-026-01242-4

Image Credits: AI Generated

DOI: 10.1038/s41575-026-01242-4

Keywords: intestinal stem cells, stem cell niche, organoids, epithelial regeneration, Wnt signaling, R-spondin, interleukin-22, cellular plasticity, short bowel syndrome, inflammatory bowel disease, tissue engineering, Intestinal Stem Cell Consortium